Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burrell

Showing results (371-380 of 381) with videos related to

Pageof 39
Sort By:
JAMA Network Open|August 26, 2025
Poststroke Cardiorespiratory Exercise for Brain Volume and Cognition: A Randomized Clinical TrialAmy Brodtmann, Leonid Churilov, Kimberley Adkins, et al.
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|July 18, 2025
Fludrocortisone to treat patients with aneurysmal subarachnoid haemorrhage: Protocol for an international, phase 3, randomised, placebo-controlled, multicentre trialJeremy Cohen, Anthony Delaney, Andrew Udy, et al.
The Journal of Clinical Endocrinology and Metabolism|May 3, 2018
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLDEveline Bruinstroop, Rinkoo Dalan, Yang Cao, et al.
Frontiers in Immunology|August 15, 2022
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Frontiers in Immunology|January 27, 2023
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Nature Biomedical Engineering|October 13, 2020
A deep-learning system for the assessment of cardiovascular disease risk via the measurement of retinal-vessel calibreCarol Y Cheung, Dejiang Xu, Ching-Yu Cheng, et al.
European Heart Journal|November 18, 2020
Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidneyXiao Jiang, James M Eales, David Scannali, et al.
Journal of the American Heart Association|June 16, 2017
Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failureFrancine Z Marques, Priscilla R Prestes, Sean G Byars, et al.
Current Problems in Cardiology|May 30, 2017
Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert ConsultationAlberto Morales Salinas, Antonio Coca, Michael H Olsen, et al.
Pageof 39

Showing results (371-380 of 381) with videos related to

Sort By:
Pageof 39
JAMA Network Open|August 26, 2025
Poststroke Cardiorespiratory Exercise for Brain Volume and Cognition: A Randomized Clinical TrialAmy Brodtmann, Leonid Churilov, Kimberley Adkins, et al.
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|July 18, 2025
Fludrocortisone to treat patients with aneurysmal subarachnoid haemorrhage: Protocol for an international, phase 3, randomised, placebo-controlled, multicentre trialJeremy Cohen, Anthony Delaney, Andrew Udy, et al.
The Journal of Clinical Endocrinology and Metabolism|May 3, 2018
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLDEveline Bruinstroop, Rinkoo Dalan, Yang Cao, et al.
Frontiers in Immunology|August 15, 2022
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Frontiers in Immunology|January 27, 2023
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Nature Biomedical Engineering|October 13, 2020
A deep-learning system for the assessment of cardiovascular disease risk via the measurement of retinal-vessel calibreCarol Y Cheung, Dejiang Xu, Ching-Yu Cheng, et al.
European Heart Journal|November 18, 2020
Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidneyXiao Jiang, James M Eales, David Scannali, et al.
Journal of the American Heart Association|June 16, 2017
Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failureFrancine Z Marques, Priscilla R Prestes, Sean G Byars, et al.
Current Problems in Cardiology|May 30, 2017
Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert ConsultationAlberto Morales Salinas, Antonio Coca, Michael H Olsen, et al.
Pageof 39